Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20305035rdf:typepubmed:Citationlld:pubmed
pubmed-article:20305035lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20305035lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:20305035lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:20305035lifeskim:mentionsumls-concept:C0206630lld:lifeskim
pubmed-article:20305035lifeskim:mentionsumls-concept:C1306673lld:lifeskim
pubmed-article:20305035lifeskim:mentionsumls-concept:C0695347lld:lifeskim
pubmed-article:20305035lifeskim:mentionsumls-concept:C1273870lld:lifeskim
pubmed-article:20305035lifeskim:mentionsumls-concept:C1522673lld:lifeskim
pubmed-article:20305035pubmed:issue10lld:pubmed
pubmed-article:20305035pubmed:dateCreated2010-9-23lld:pubmed
pubmed-article:20305035pubmed:abstractTextTo explore whether adjuvant treatment options may impact on the prognosis in localized endometrial stromal sarcomas (ESSs; stages I and II). The historical options usually discussed in addition to hysterectomy and bilateral salpingoophorectomy (BSO) are active surveillance, pelvic radiotherapy, chemotherapy and hormonal therapy, alone or in combination.lld:pubmed
pubmed-article:20305035pubmed:languageenglld:pubmed
pubmed-article:20305035pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20305035pubmed:citationSubsetIMlld:pubmed
pubmed-article:20305035pubmed:statusMEDLINElld:pubmed
pubmed-article:20305035pubmed:monthOctlld:pubmed
pubmed-article:20305035pubmed:issn1569-8041lld:pubmed
pubmed-article:20305035pubmed:authorpubmed-author:DuvillardPPlld:pubmed
pubmed-article:20305035pubmed:authorpubmed-author:ReyAAlld:pubmed
pubmed-article:20305035pubmed:authorpubmed-author:MoricePPlld:pubmed
pubmed-article:20305035pubmed:authorpubmed-author:LazarVVlld:pubmed
pubmed-article:20305035pubmed:authorpubmed-author:LhomméCClld:pubmed
pubmed-article:20305035pubmed:authorpubmed-author:Haie-MederCClld:pubmed
pubmed-article:20305035pubmed:authorpubmed-author:DuclosJJlld:pubmed
pubmed-article:20305035pubmed:authorpubmed-author:PautierPPlld:pubmed
pubmed-article:20305035pubmed:authorpubmed-author:BalleyguierCClld:pubmed
pubmed-article:20305035pubmed:authorpubmed-author:MaloufG GGGlld:pubmed
pubmed-article:20305035pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20305035pubmed:volume21lld:pubmed
pubmed-article:20305035pubmed:ownerNLMlld:pubmed
pubmed-article:20305035pubmed:authorsCompleteYlld:pubmed
pubmed-article:20305035pubmed:pagination2102-6lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:meshHeadingpubmed-meshheading:20305035...lld:pubmed
pubmed-article:20305035pubmed:year2010lld:pubmed
pubmed-article:20305035pubmed:articleTitleImpact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma.lld:pubmed
pubmed-article:20305035pubmed:affiliationDepartment of Medicine, Institut Gustave-Roussy, 39 rue Camille Desmoulins, Villejuif, France.lld:pubmed
pubmed-article:20305035pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20305035pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed